Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.7%

6 terminated/withdrawn out of 29 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

24%

7 trials in Phase 3/4

Results Transparency

61%

11 of 18 completed trials have results

Key Signals

2 recruiting11 with results6 terminated

Enrollment Performance

Analytics

Phase 2

8(38.1%)

N/A

4(19.0%)

Phase 3

4(19.0%)

Phase 4

3(14.3%)

Phase 1

2(9.5%)

21Total

Phase 2(8)

N/A(4)

Phase 3(4)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT04288323Phase 4Completed

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

Role: collaborator

NCT05924672Phase 2Active Not Recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Role: collaborator

NCT02387229Phase 3Terminated

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Role: collaborator

NCT06993246Not ApplicableNot Yet Recruiting

Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?

Role: collaborator

NCT06024746Phase 3Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Role: collaborator

NCT06033950Phase 3Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

Role: collaborator

NCT02533960Completed

Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime

Role: collaborator

NCT02582749Phase 2Terminated

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Role: collaborator

NCT02204267Not ApplicableCompleted

Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke

Role: collaborator

NCT02306824Completed

Berlin Atrial Fibrillation Registry

Role: collaborator

NCT02459119Phase 2Completed

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

Role: collaborator

NCT02425683Phase 2Terminated

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Role: collaborator

NCT00383994Phase 1Completed

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

Role: collaborator

NCT01009684Completed

International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens

Role: collaborator

NCT01005875Not ApplicableTerminated

Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

Role: collaborator

NCT01360996Phase 4Completed

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Role: collaborator

NCT00864383Phase 3Completed

Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis

Role: collaborator

NCT01122056Not ApplicableCompleted

Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis

Role: collaborator

NCT01338857Phase 2Terminated

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

Role: collaborator

NCT00712790Phase 1Completed

Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

Role: collaborator